- Country: USA
- Summary: Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formular Additional Discount Program
- UST Ref No: 125591325
- Deadline: 18 Sep 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: HT9402-25-Q-9403
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following November 2025 drug classes/subclass or newly approved drugs will be reviewed:
a. Anzupgo - Atopy - Subclass: N/Ab. Brinsupri - Pulmonary-1 Agents - Subclass: N/Ac. Brynovin - Diabetes Non-Insulin - Subclass: DPP-4 Inhibitorsd. Ekterly - Corticosteroids-Immune Modulators - Subclass: Hereditary Angioedema Agentse. Harliku - Metabolic Agents-Miscellaneous - Subclass: Replacement Enzymesf. Hernexeos - Oncological Agents - Subclass: N/Ag. Kirsty - Insulins - Subclass: Rapid-Acting Agents U-100h. Lopressor - Beta Blockers and Hydrochlorothiazide Combinations - Subclass: N/Ai. Modeyso - Oncological Agents - Subclass: N/Aj. Orlynvah - Antibiotics - Subclass: Beta-lactamsk. Sephience - Metabolic Agents-Miscellaneous - Subclass: N/Abr... - Documents:
Price-List-Anzupgo-Atopy-NA.xlsx
Price-List-Brinsupri-Pulmonary-1-Agents-NA.xlsx
Price-List-Brynovin-Diabetes-Non-Insulin-DPP.xlsx
Price-List-Ekterly-Corticosteroids-Immune-Modu.xlsx
Price-List-Harliku-Metabolic-Agents-Miscellane.xlsx
Price-List-Hernexeos-Oncological-Agents-NA.xlsx
Price-List-Kirsty-Insulins-Rapid-Acting-Agen.xlsx
Price-List-Lopressor-Beta-Blockers-and-Hydroch.xlsx
Price-List-Modeyso-Oncological-Agents-NA.xlsx
Price-List-Orlynvah-Antibiotics-Beta-lactams.xlsx
Price-List-Sephience-Metabolic-Agents-Miscella.xlsx
DoD-Formulary-Placement-of-FDA-Newly-Approved-Drug.pdf
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINDepartment of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formular Additional Discount Program - USA Tender
The DEPT OF DEFENSE | DEFENSE HEALTH AGENCY (DHA), a Government sector organization in USA, has announced a new tender for Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formular Additional Discount Program. This tender is published on USARFP under UST Ref No: 125591325 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-09-18.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
